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Abstract: Once ingested, most of the alcohol is metabolized in the liver by alcohol dehydrogenase
to acetaldehyde. Two additional pathways of acetaldehyde generation are by microsomal ethanol
oxidizing system (cytochrome P450 2E1) and catalase. Acetaldehyde can form adducts which can
interfere with cellular function, leading to alcohol-induced liver injury. The variants of alcohol
metabolizing genes encode enzymes with varied kinetic properties and result in the different rate
of alcohol elimination and acetaldehyde generation. Allelic variants of these genes with higher
enzymatic activity are believed to be able to modify susceptibility to alcohol-induced liver injury;
however, the human studies on the association of these variants and alcohol-associated liver disease
are inconclusive. In addition to acetaldehyde, the shift in the redox state during alcohol elimination
may also link to other pathways resulting in activation of downstream signaling leading to liver injury.
Keywords: alcohol metabolizing enzyme; cytochrome P450 2E1; and alcohol-associated liver disease
1. Introduction
Alcohol associated liver disease (ALD) is one of the major causes of chronic liver disease
worldwide [1,2]. The risk of ALD development is known to be associated with the quantity of alcohol
(beverages containing ethanol) consumed [3,4]. Early studies suggested that a long-term consumption
of more than 80 g per day was correlated with increased risk of cirrhosis, but subsequent estimates of
the harmful drinking threshold have been below this level, especially for women [5,6]. In another study,
13,285 subjects were prospectively followed for 12 years to determine the association between the risk
for development of future liver disease and self-reported alcohol consumption [7]. The patients were
asked in multiple-choice form on the type of alcoholic beverages they consumed, wine (glasses), beer
(bottles), or spirits (units) and frequency (i.e., daily, weekly, monthly, and hardly/never). If daily alcohol
intake was reported, the average number of beverages of each type per week was recorded. In this
study, one beverage equals to 12 g of alcohol [7]. There was no apparent risk of alcohol-induced liver
injury if the range of alcohol consumption was between 1 to 6 beverages per week (12–72 g per week);
however, drinking beyond this level (7 to 13 beverages (84–156 g) per week for women and 14 to
27 beverages (168–324 g) per week for men) resulted in a significant rise in the relative risk of alcohol
associated liver disease [7]. In addition to the quantity of alcohol consumption, studies also suggested
Biomedicines 2020, 8, 50; doi:10.3390/biomedicines8030050 www.mdpi.com/journal/biomedicines
Biomedicines 2020, 8, 50 2 of 16
that the risk of ALD may also depend on the patterns and types of alcohol intake independently of
the level of alcohol consumption [8]. Red wine drinkers may have a lower risk of ALD compared to
other beverage drinkers [9]. It is currently unknown whether this is due to an effect of the red wine
per se or to confounding protective lifestyle factors. Of importance, it is difficult to systematically
study the relationship between the quantity of alcohol consumption and the development of ALD
because data collection always involves rough estimate, differences in drinking patterns among studies,
and inconsistencies in data collection tools. ALD represents a range of pathological changes ranging
from steatosis, alcoholic steatohepatitis, advanced fibrosis, and cirrhosis [1,10]. Alcoholic steatosis
can occur in patients who consumed 120–150 g of alcohol per day for 2–3 weeks [11]. Most cases
develop macrovesicular steatosis primarily in zone 3 or throughout the liver in severe cases [12]. This
condition is reversible upon abstinence [13]. Hepatic steatosis was thought to be a benign condition;
however, a subset of patients can progress to fibrosis or cirrhosis in 10 years, especially if the drinking
continues [14].
Only a group of patients with excessive alcohol use develop alcoholic hepatitis, a severe
manifestation of ALD with high morbidity and mortality [15–17]. Approximately, 10% to 20%
of patients with alcoholic hepatitis are likely to progress to cirrhosis annually, and up to 70% of patients
with alcoholic hepatitis ultimately will become cirrhotic [12]. Abstinence is essential and has the impact
on the survival [15,18]. Overall, 15% to 20% of excessive drinkers will progress to advanced liver
disease and cirrhosis [19]. Once developed, patients with alcoholic cirrhosis have clinical presentations
and complications similar to those with other types of cirrhosis. Of importance, mortality due to
alcoholic cirrhosis has been shifted towards a younger population between 25 and 34 years old [20].
There are also important gender differences in ALD pathogenesis. At any given level of alcohol
consumption, women have a higher likelihood of developing ALD than men [5]. The mechanism is
likely due to lower volume of distribution in women leading to higher blood alcohol concentrations
per unit of alcohol consumed [21]. Additionally, recent studies also showed the role of hormone
like estrogen which can increase gut permeability and endotoxemia leading to the increase in the
production of inflammatory cytokines by Kupffer cells and risk of ALD [22]. Some of the enzymes
involved in alcohol metabolism are genetically polymorphic leading to the alteration in enzymatic
properties and varying amounts of acetaldehyde generation after alcohol consumption [23]. The roles
of these enzymes in association with ALD are the subject of this overview.
2. Alcohol Metabolism
When alcohol is ingested, a small amount is immediately metabolized in the stomach. Most of the
remaining alcohol is subsequently absorbed from the gastrointestinal tract, primarily the stomach and
upper small intestine [24]. After the absorption, alcohol is transported to the liver through the portal
vein, where the alcohol concentration is significantly higher than that measured from the peripheral
blood [25]. Absorption rate of ethanol is a first-order kinetic process in proportion to the concentration
of alcohol in the stomach. Once the gastric alcohol concentration decreases, the rate of absorption slows
down [26]. After the initial passage through the liver; the remainder of the ingested alcohol enters
systemic circulation and is distributed throughout the body’s tissues. Once the rate of absorption is
equal to the rate of alcohol metabolism (approximately 10–30 mg% per hour), the peripheral blood
alcohol concentration reaches a maximum point and starts to decline as alcohol is eliminated from the
body [27].
Liver is the major organ which metabolizes more than 90% of ingested alcohol into acetaldehyde
through several enzymatic and non-enzymatic mechanisms [28,29]. Many of the effects of ethanol are
mediated by its byproduct acetaldehyde, which is mainly generated by alcohol dehydrogenase (ADH),
cytochrome P450 2E1 (CYP2E1), and catalase (Figure 1). Acetaldehyde is subsequently converted to
acetate by aldehyde dehydrogenases (ALDH), which is released from the liver and metabolized by
muscle and heart [29]. The rate of ethanol metabolism by alcohol metabolizing enzymes may be critical
in determining its toxicity because of the toxic intermediates.
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Figure 1. The major pathways of acetaldehyde formation after alcohol ingestion, alcohol 
dehydrogenase (ADH), cytochrome P450 2E1 (CYP2E1), catalase, and aldehyde dehydrogenase 
(ALDH) are demonstrated with their cofactors, and substrates. 
3. Alcohol Metabolizing Enzymes 
3.1. Alcohol Dehydrogenase (ADH) 
ADH is a zinc-dependent enzyme located in the cytosol. It uses NAD+ as a cofactor and is 
responsible for the majority of alcohol oxidation in the liver [30,31]. Human ADHs are categorized 
into five classes based on their structural and kinetic characteristics [23,29]. These enzymes are 
dimeric and identified by Greek letters with a molecular weight of 40kDa per subunit [23,29]. Under 
physiological conditions, the main isoenzymes involved in human ethanol metabolism are ADHs 
from classes I, II, and IV [23,29].  
Class I ADH contains α, β, and γ isoenzymes. These enzymes have a low Michaelis constant 
(Km) < 5 mM for ethanol and therefore play a significant role in ethanol metabolism [23]. Class I ADH 
is highly abundant in the liver and is sensitive to inhibition by pyrazole derivatives [32]. Class I ADH 
consists of three genes, ADH1A, ADH1B, and ADH1C, making up gene clusters located on 
chromosome 4q21-23, spanning about 80 kb [33]. Among these genes, polymorphisms with 
physiological significance exist in the ADH1B and ADH1C loci [23]. These variants result in the 
difference in their efficiency for ethanol oxidation. People of different racial backgrounds inherit 
different sets of ADH isoenzymes [29,34,35]. African Americans who carry a copy of the ADH1B*3 
gene, encoding an enzyme with high maximum velocity, have a somewhat faster alcohol metabolism 
rate [36,37]. Class II ADH (π ADH) has a higher Km for ethanol and is less sensitive to pyrazole 
inhibition than class I enzymes [38]. Because of its Km, its role in ethanol metabolism is less than that 
of Class I ADH [39]. Class III ADH is ubiquitous and it can metabolize longer chain alcohols as well 
as ω-oxidation of fatty acid [40]. The class IV ADH (µ-ADH, for the mucosal isozyme or σ-ADH, for 
the stomach isoenzyme) has been found in the esophagus and stomach and is responsible for alcohol 
first pass metabolism [41]. Among ADHs, σ-ADH has the highest Vmax and is very active towards 
retinol. This may be pertinent to its expression at the epithelia, which are dependent on retinol for 
their integrity [42]. The kinetic properties of each ADH class, population and tissue distribution are 
shown in Table 1.  
Table 1. The kinetic properties of each ADH class, population, and tissue distribution [23,29]. 
Gene Locus Subunit Km for Ethanol (mM) 
Vmax 
(min−1) Major Ethnicity 
Tissue 
Distribution 
Class I      
ADH1B*1 β1 0.05 54 Caucasians, African-
Americans 
Liver, lung 
ADH1B*2 β2 0.9 - Asians 
ADH1B*3 β2 34 - African-Americans 
ADH1C*1 γ1 1 - All groups 
Liver, stomach 
ADH1C*2 γ2 0.63 - Caucasians 
Class II: ADH2 π 34 40  Liver 
Figure 1. The major pathways of acetaldehyde formation after alcohol ingestion, alcohol dehydrogenase
(ADH), cytochrome P450 2E1 (CYP2E1), catalase, and aldehyde dehydrogenase (ALDH) are
demonstrated with their cofactors, and substrates.
3. Alcohol Metabolizing Enzymes
3.1. Alcohol Dehydrogenase (ADH)
ADH is a zinc-dependent enzyme located in the cytosol. It uses NAD+ as a cofactor and is
responsible for the majority of alcohol oxidation in the liver [30,31]. H man ADHs are categorized into
five classes based on their structural and kinetic characteristics [23,29]. These enzymes are dimeric an
identified by Greek letters with a molecular weight of 40kDa per subunit [23,29]. Under physiological
conditions, the main isoenzymes involved in human ethanol metabolism are ADHs from classes I, II,
and IV [23,29].
Class I ADH contains α, β, and γ isoenzymes. These enzymes have a low Michaelis constant (Km)
< 5 mM for ethanol and therefore pl y a significant role in ethanol metabolism [23]. Class I ADH is highly
abundant in the liver and is sensitive to inhibition by pyraz le deriv tives [32]. Class I ADH consists of
three genes, ADH1A, ADH1B, and ADH1C, making up ge e clusters locat d on chromosome 4q21-23,
spanning about 80 kb [33]. mong these genes, polymorphisms with physiological significance exist i
the ADH1B and ADH1C loci [23]. These variants result in the differ nce in their efficiency for ethanol
oxidation. People of different racial backgrounds i herit different sets of ADH isoenzymes [29,34,35].
African Americans who carr a copy of the ADH1B*3 g ne, nco ing an enzyme with high maximum
velocity, have a somewhat faster alcohol metabolism rate [36,37]. Class II ADH (pi ADH) has a higher
Km for ethanol d is less sensitive to pyrazole inhibition than class I enzym s [38]. Because f its
Km, its role in ethanol metabolism is less than t at of Class I ADH [39]. Class III ADH is ubiquitous
a d it ca metabolize longer chain alcohols as well as ω- xidation of fatty acid [40]. The class IV
ADH (µ-ADH, for the mucosal isozyme or σ-ADH, for the stomach isoe zyme) has been found in
the es ph gus and stomach and is r sponsible for alcohol first pass etabolism [41]. Among ADHs,
σ-ADH h s the highest Vm x and is very activ towards retinol. This may be pertinent to its expression
at the epitheli , which are dependent on retinol for their integrity [42]. The kinetic properti s f each
ADH class, population and tissue distribution are shown in Table 1.
Table 1. The kinetic properties of each ADH class, population, and tissue distribution [23,29].
Gene Locus Subunit Km for Ethanol (mM) Vmax (min−1) Major Ethnicity Tissue Distribution
Class I
ADH1B*1 β1 0.05 54 Caucasians,African-Americans Liver, lung
ADH1B*2 β2 0.9 - Asians
ADH1B*3 β2 34 - African-Americans
ADH1C*1 γ1 1 - All groups Liver, stomach
ADH1C*2 γ2 0.63 - Caucasians
Class II: ADH2 pi 34 40 Liver
Class III: ADH3 χ 1000 - Ubiquitous
Class IV: ADH4 σ, µ 20 1510 Stomach and esophagus
“-“: no data available.
Tissue distribution of ADH: ADH mRNAs are expressed in a variety of tissues with high levels of
class I ADH in the liver, stomach, kidney, and colon, and with lower levels in lung, small intestine,
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brain, and muscle [43]. Of importance, class I ADH is also found in blood vessels, which may be linked
to alcohol-induced flushing. Class II ADH was found in the liver and duodenum [43]. σ-ADH is
primarily found in the gastric mucosa, though its expression is absent in approximately one-third of the
Asians population [44]. Microorganisms can produce alcohol [45,46] and express numerous forms of
alcohol dehydrogenase, which can contribute to the formation of acetaldehyde in the gastrointestinal
tract, or wherever microbial overgrowth occurs [47,48].
Regulation of ADH expression: The promotors of hepatic ADH1 can interact with ubiquitous
transcription factors (i.e., upstream stimulatory factor [USF], TATAA binding factors and CAAT
box-binding transcription factor/nuclear factor-1 [CTF/NF-I]), and tissue-specific factors (i.e.,
CCAAT-enhancer binding proteins [C/EBPα and β] hepatocyte nuclear factor 1 [HNF-1], and D-box
binding protein [DBP]) [49–52]. An HNF-1 site was found to serve as a key regulator for all three class
I genes [53]. Upstream regions of ADH1 genes are also found to be the binding sites for retinoic acid,
glucocorticoid and thyroid hormones [23,54–56]. Hepatic ADH activity also depends on the route of
alcohol administration. While the quantity of ethanol consumed from liquid diets did not modify
hepatic ADH activity, higher doses of ethanol administered by intragastric infusion induced hepatic
ADH activity due to the induction of the transcription factor C/EBPβ and suppression of C/EBPγ and
a truncated, inhibitory form of C/EBPβ [57]. Additionally, intragastric ethanol infusion can induce
hepatic Class I ADH mRNA, protein, and activity levels by 3.9-, 3.3-, and 1.7-fold, respectively through
transcription factor USF due to the increase in endotoxin in the portal system [57,58].
Level of alcohol concentration and ADH: Because of the low Km of Class I ADH, this enzyme
is saturated with any types of drinking patterns once blood alcohol concentration >15–20 mg% [27].
While class I ADH with low Km for ethanol is active even at a low alcohol concentration, those with
high Km (i.e., σ-ADH) are more active when blood ethanol concentrations are high or in tissues of
the upper gastrointestinal tract that are directly exposed to beverage ethanol. Modelling of ethanol
oxidation indicated that ethanol metabolism by ADH is regulated by the quantity of ADH enzymes,
the byproduct acetaldehyde, and the NADH to NAD+ ratio in the cytosol [59,60].
3.2. Microsomal Ethanol Oxidizing System
In addition to ADH, ethanol can be oxidized by a microsomal ethanol oxidizing system (MEOS)
involving primarily the cytochrome P450 2E1 (CYP2E1) [61]. Two other cytochromes contribute
to the MEOS, albeit to a lesser extent, CYP1A2 and CYP3A4 [62–64]. CYP2E1 is associated with
NADPH-cytochrome P450 reductase in the endoplasmic reticulum and reduces oxygen molecule to
water when ethanol is oxidized to acetaldehyde [61]. It has a low ethanol catalytic efficiency with
the Km for ethanol ~10 mM when compared to ADH and therefore is responsible for a minor role
and accounting for approximately 10% of ethanol metabolism [65]. However, CYP2E1 may assume a
greater role at high blood alcohol concentrations. The levels of CYP2E1 are induced by chronic alcohol
consumption (more detail in section below) notably in the perivenular zone leading to the increase in
alcohol elimination rate among excessive drinkers [23]. In addition, it is induced in diabetes, high fat
diet, and fasting, which may relate to its ability to oxidize the ketone body acetone [66–69]. CYP2E1 is
a major contributor of oxidative stress in the hepatocytes by generating several reactive oxygen species
(ROS) such as hydrogen peroxide (H2O2), hydroxyethyl radical (HER·), hydroxyl radical (OH−) and
superoxide (O2−) [64,67].
Regulation of CYP2E1 expression: The human CYP2E1 gene spans 11 kb, contains 9 exons,
and contains a typical TATAA box [70]. Its expression is regulated at the transcriptional (mRNA) level
by ethanol concentration [71] and at the post translational level by protein stabilization and reducing
the proteasomal degradation [64]. The expression of CYP2E1 can also be induced by cytokines such
as interleukin-4 [72]. CYP2E1 can also be regulated by hsa-miR-214–3p [73]. In a HepG2-derived
CYP2E1 over-expression cell model, hsa-miR-214-3p showed strong suppression of CYP2E1 expression
by targeting the coding region of its mRNA transcript [73]. Treatment with hsa-miR-214-3p mimics
partially blocked ethanol-dependent increases in CYP2E1 mRNA and protein levels in HepG2 cells [73].
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Level of alcohol concentration and CYP2E1: Since CYP2E1 has a high Km for ethanol, it will
generate acetaldehyde at a high level of ethanol concentrations [23]. CYP2E1 plays a more important
role in alcohol metabolism when high blood concentration is reached. Another important aspect of
CYP2E1 is that binge drinking can induce its activity, making it more effective in alcohol metabolism at
its higher blood concentration [74]. Additionally, the increase in enzyme activity is the underlying
mechanism to explain faster alcohol clearance among excessive drinkers [63]. Unlike ADH, it does
not appear that CYP2E1 is inhibited by acetaldehyde; in fact, CYP2E1 can oxidize acetaldehyde to
acetate, but not in the presence of ethanol [23]. Because CYP2E1 also metabolizes several medications,
excessive drinkers with the induction in CYP2E1 activity will demonstrate increased metabolic rates
for those medications which may lead to adverse consequences [75].
3.3. Catalase
The peroxisomal catalase, a tetrameric, heme-containing enzyme, converts hydrogen peroxide
(H2O2) to oxygen and water [76]. Catalase can also oxidize ethanol to acetaldehyde as the end product
in an H2O2-dependent fashion, though this is not a key pathway for ethanol elimination [23,77].
Tissue distribution of catalase: Catalase is ubiquitously expressed in almost all tissues. Catalase is
also expressed by colonic floras which may lead to acetaldehyde production in the lower gastrointestinal
tract [78,79].
Regulation of catalase expression: In rodents, catalase gene is a single-copy gene with 33 kb. The
promoter region of this gene lacks a TATAA box and an initiator consensus sequence [23]. It contains
multiple transcription initiation sites as well as multiple CCAAT boxes and GC boxes [23]. The increase
in catalase activity was reported after chronic ethanol feeding [80]. The rat catalase promoter contains
a peroxisome proliferator responsive element (PPRE), therefore it can be induced by peroxisome
proliferators [81].
Level of alcohol concentration and catalase: Catalase activity relies on the cellular level of H2O2.
The ability of catalase to metabolize ethanol may be increased under oxidative stress with the increase
in cellular H2O2 production [82]. This was observed with perfused rat liver, when fatty acids were
added and the process of peroxisomal β oxidation lead to the generation of H2O2 and oxidation of
ethanol. This raises the possibility that under conditions of oxidant stress (and H2O2 production)
catalase-mediated ethanol oxidation may be increased [23].
3.4. Aldehyde Dehydrogenase (ALDH)
The second step of ethanol metabolism is the process to convert acetaldehyde to acetate by
alcohol dehydrogenase (ALDH). ALDH enzymes use NAD+ as a cofactor during the oxidization of
acetaldehyde but are expressed in a wider range of tissues than the ADH isoenzymes [83]. In addition
to its role in elimination of acetaldehyde, ALDH also plays a critical role in the detoxification of lipid
peroxidation byproduct such as 4-hydroxynonenal (4-HNE) which is generated during oxidative
stress [84]. There are two major ALDH isoforms, cytosolic and mitochondrial, encoded by the aldehyde
ALDH1 and ALDH2 genes, respectively. Of the two isoforms, mitochondrial ALDH2 plays the central
role in human acetaldehyde metabolism because of its submicromolar Km for acetaldehyde [29]. Tissue
distribution and Km for acetaldehyde of human ALDHs are shown in Table 2.
Table 2. Km for acetaldehyde and tissue distribution of human aldehyde dehydrogenase (ALDH) [23,29].
Gene Locus Km for Acetaldehyde Tissue Distribution
Class I ALDH1 30 µM Liver and many other tissues
Class II ALDH2 <1 µM Low levels in most tissues with the expression highest in livercompared to kidney and muscle
Class III ALDH3 11 mM Stomach, liver, cornea
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Regulation of ALDH2 expression: ALDH2 expression can be regulated at the transcriptional
level [85]. ALDH2 gene promoter contains a nuclear receptor response element that is bound by
retinoic acid receptors, peroxisome proliferator activated receptors (PPARs), hepatocyte nuclear
factor 4 (HNF4), and members of the chicken ovalbumin upstream promoter transcription factor
(COUP-TF) family [85–87]. ALDH2 activity can also be modified through post-translational regulation
by serine/threonine phosphorylation through epsilon protein kinase C (εPKC) [84]. Additionally, the
activation of ALDH2 by ethanol has been shown to be mediated by epigenetic regulation through
hyperacetylation of ALDH2 gene by sirtuin 3 (SIRT3) inactivation [88].
3.5. Other Minor Pathways for the Generation of Acetaldehyde
Cytosolic fractions of xanthine oxidoreductase such as hypoxanthine, xanthine, and caffeine
can oxidize ethanol to acetaldehyde [89]. This process can be inhibited by allopurinol and not
by pyrazole [89]. Ethanol can also be metabolized to acetaldehyde and 1-hydroxyethyl radical by
cytochrome P450 reductase [90]. There are other reports that other oxidant species (hydroxyl radical)
formed non-enzymatically might be able to oxidize ethanol to acetaldehyde. In addition, acetaldehyde
can be formed during the degradation of threonine, putatively by threonine aldolase [23,29].
4. Genetic Polymorphisms of Alcohol-Metabolizing Enzymes and ALD
ADH: Because of the differences in the enzymatic activity to metabolize alcohol to acetaldehyde,
it has been postulated that those with alleles encoding for higher enzymatic activity such as ADH1B*2
and ADH1C*1 alleles, are at increased risk of developing ALD and modifying the risk for alcohol
dependence due to higher acetaldehyde exposure at any given alcohol concentration [91,92]. ADH1B*2
allele has been shown to reduce the occurrence of alcohol abuse especially in population with high
prevalence such as Jewish and Asian populations [29]. Several other studies also found similar
results on the higher frequency of ADH1B*2 among moderate or non-drinkers compared to heavy
drinkers [93–95]. The reason behind these findings is likely due to the development of unpleasant
side effects associated with the faster accumulation of acetaldehyde after alcohol consumption [96],
though the levels of venous acetaldehyde concentration in those with and without this allele have
not previously shown to be different [97,98]. A recent study from Japan found that those with
slow metabolizing ADH1B enzyme increase susceptibility to hepatic steatosis in men with alcohol
dependence [99]. However, to date, the results on the association between genetic variants of ADH
and ALD have been inconsistent, owing to the difference in the ethnicities of the study cohorts and
limitations in sample size, as well as the low allele frequency of ADH1B*2 among Caucasians [92].
CYP2E1: The CYP2E1 c1 allele is located in the 5’-flanking region of the CYP2E1 gene while
in vitro transcriptional assays showed the c2 allele to be more active enzyme [100,101]. The allele
frequency of CYP2E1 variants is varied depending on ethnicity, the c2 variant is found at a higher
frequency in East Asians (~25–35%) than that in Caucasians (~2–8%) [23,102]. In contrast to ADH,
CYP2E1 is inducible and its activity can increase significantly after alcohol consumption [23], causing a
higher level of reactive oxygen species and acetaldehyde [103]. The allele frequency of c2 variant is
higher than that of c1 in patients with ALD, compared with random population controls [92]. However,
the association between CYP2E1 variants and ALD is inconclusive [92].
Catalase: Transcription of the catalase gene is influenced by the -262 C/T and -844 A/G
polymorphisms. A common polymorphism -262 C/T in the promoter region has been found to
be associated with altered catalase activities and is associated with the susceptibility to alcohol
dependence [104,105]. To date, there is no convincing evidence on the role of catalase polymorphism
and ALD.
ALDH: Similar to ADH and CYP2E1 variants, polymorphisms in the ALDH2 demonstrate a
vital role in regulating ALDH2 activity and are hypothesized to alter genetic susceptibility to alcohol
dependence and alcohol-induced liver diseases. A variant at exon 12 predicts lysine at residue
504 instead of glutamic acid [106]. The common form of the SNP (rs671) (504glu) encodes the glu
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(G) allele (previously referred to as the ALDH2 *1 allele); the 504lys (A, formerly ALDH2 *2 and
487lys) allele produces an inactive isozyme and thus limits its activity to convert acetaldehyde into
acetate [106,107]. Individuals with the lys allele tend to have the accumulation of acetaldehyde after
alcohol ingestion with the peak acetaldehyde concentration approximately 6- to 19-fold higher in those
with heterozygotes or homozygotes for 504lys allele than those with common allele [97]. These patients
commonly experience unpleasant side effects such as nausea, vomiting, or flushing after alcohol
ingestion [108,109]. ALDH2 is inhibited by disulfiram (Antabuse) and consumption of alcohol while
taking disulfiram or a number of other drugs such as metronidazole results in the accumulation of
acetaldehyde, producing vasodilation, facial flushing, tachycardia, nausea, and vomiting [37]. Variants
in genes encoding ALDH2 are important determinants of risk for alcohol abuse or dependence and to a
lesser extent for cirrhosis, especially in Asian populations [92]. Previous studies have shown that the
inactive ALDH2 504lys allele occurred mainly in Asians [29,37]. Most patients with alcohol abuse or
dependence with inactive ALDH2 alleles were heterozygous while homozygous lys/lys was rarely
found, although it was often observed in controls [106]. These findings are consistent with what we
observed in our study [110]. ALDH2 504lys allele is reported to be less prevalent in patients with
alcoholic cirrhosis than that in controls [110]. Depending on the geographic region, the allele frequency
for 504lys has been reported to be up to 40% among East Asian population [111], however, its frequency
among patients with ALD is around 1.0%–11.6%, depending on the population being studied [106].
Taken together, there are several evidence linking the genetic variants of alcohol metabolizing enzyme
genes with the risk of alcoholism/alcohol dependence; however, the association of these variants and
ALD is still inconclusive.
5. Ethanol Metabolism and Its Association in ALD Pathogenesis
5.1. Redox State Alterations and ALD
Ethanol metabolism by alcohol metabolizing enzymes leads to the changes in intracellular redox
state which may underlie the pathogenesis of ALD. One of the earliest responses to excessive alcohol
use is the development of hepatic steatosis secondary to the accumulation of triglyceride droplets in
the hepatocytes [10]. One of the pathophysiological mechanisms leading to hepatic steatosis is the
imbalance between triglyceride synthesis and the ability to oxidize or export it in the form of very
low-density lipoprotein (VLDL) particles [10]. Increasing intracellular NADH levels secondary to
ethanol metabolism from ADH and ALDH inhibit fatty acid oxidation [112]. Additionally, the induction
of a few enzymes involved in fatty acid synthesis as well as increase in the intracellular level of fatty
acids and L-glycerol-3-phosphate result in the increase in the synthesis of triglycerides [10,113]. The
change in the intracellular redox state leading to triglyceride accumulation has been confirmed in cell
lines with stably expressed ADH. These cell lines can oxidize ethanol resulting in the alterations in
intracellular redox potential as indicated by an increase in the lactate/pyruvate ratio. More importantly,
they can accumulate large amounts of triglyceride upon alcohol treatment [114].
The alterations in the redox state, among several mechanisms, may interfere with sirtuin-1 (SIRT-1),
a nicotinamide adenine dinucleotide (NAD+, NADH)-dependent class III histone deacetylase [115,116].
Ethanol-mediated SIRT1 inhibition may lead to hyper-acetylation of a set of molecules including histone
H3, transcription factors such as sterol regulatory element-binding protein (SREBP) and peroxisome
proliferator-activated receptor alpha (PPARα) [116]. This subsequently leads to the alterations in
several downstream pathways which are involved in inflammatory responses and lipid metabolism
leading to the development of ALD (see more detail in [116]).
5.2. Role of Oxidative Stress
As previously mentioned, CYP2E1 is induced by chronic alcohol use and is “leaky,” in that electrons
transferred to it from CYP450 reductase can eventually be transferred to oxygen molecule forming
superoxide [67,117]. The consequence of intracellular oxidative stress is lipid peroxidation [118], a
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reaction of lipid radical formation that follows the removal of an electron from polyunsaturated fatty
acid (PUFA) [118,119]. The lipid free radical then form a lipid hydroperoxide with the addition of
oxygen molecule, and ultimately decomposition to form reactive aldehydes such as 4-hydroxynonenal
(4-HNE) and malondialdehyde (MDA) [120–123]. ALD has been shown to be associated with increase
in lipid peroxidation, formation of 1-hydroxyethyl radical and lipid radicals, and decrease in hepatic
antioxidants, especially glutathione [67,82,124]. In addition to the role of CYP2E1-induced oxidative
stress, alcohol can also acetylate mitochondrial superoxide dismutase and impact its antioxidant
ability [125]. Changes in diets that either promote or reduce oxidative stress have an impact on
the degree of liver injury. When PUFA were substituted with either medium-chain triglycerides or
saturated fats, the extent of alcohol-induced liver injury was ameliorated because of the reduction in
lipid peroxidation [126,127]. CYP2E1 may be an important regulator of liver injury in obese patients
with excessive alcohol use. Obesity is an independent risk factor for hepatic steatosis, alcoholic
hepatitis, and cirrhosis among excessive drinkers [8,128]. Obesity and alcohol synergistically enhance
the degree of liver injury [129,130]. Several studies indicate combined pathological effects of alcohol
and obesity or fatty acid levels, respectively, on hepatocellular lipid accumulation and injury as well
as hepatic inflammation, fibrosis, and cancerogenesis [130]. The induction of CYP2E1 is commonly
observed in patients with excessive alcohol use and interestingly it can also be activated in the presence
of obesity and metabolic syndrome by increasing levels of fatty acids [63,131,132]. The co-activation of
CYP2E1 by both ethanol and endogenous substrates such as fatty acids, can augment the severity and
accelerate the progression of liver injury [132,133]. In fact, a recent study in a cohort of 233 patients
with alcoholic hepatitis from the United Kingdom and United States demonstrated that obesity is
common in AH and associated with a greater than two-fold increase in short-term mortality [134].
5.3. Role of Protein Adduct Formation
Protein adducts formation during alcohol-induced liver injury are covalent linkages developed
between amino acid side chains of liver proteins and compounds such as acetaldehyde, and byproducts
of lipid peroxidation 4-HNE and MDA [135]. Once generated, acetaldehyde can form the covalent
linkages with amino acid side chains of hepatic proteins to form acetaldehyde adducts. These adducts
are located primarily in the perivenous region and develop early in the process of alcohol-induced
liver injury [136]. Once the disease progresses, they are prevalent in areas of inflammation and
fibrosis [137,138]. It has been well documented that these adducts elicit an immune response and can
interfere with the functions of proteins especially at the lysine residues [139], such as lysine-dependent
enzymes as well as cytoskeletal proteins [140]. There are reports that show acetaldehyde adducts
can impair microtubule function leading to defects in protein transport which in turn attributes to
endoplasmic reticulum stress in alcohol-induced liver injury [140].
6. Conclusions
ADH, CYP2E1, and catalase can generate acetaldehyde after alcohol ingestion. The ability
of acetaldehyde to alter cellular function will depend on the enzymatic activity and acetaldehyde
formation. Because of the differences in the capacity to metabolize alcohol to acetaldehyde, it has
been suggested that individuals with high activity of alcohol metabolizing enzymes are susceptible
to alcohol-induced liver injury due to a higher level of acetaldehyde exposure. However, the results
on the allelic variants of the genes encoding for ADH, CYP2E1 genes, and ALD are inconclusive.
Alcohol metabolizing enzyme, notably CYP2E1, may be an important regulator leading to liver injury
especially in obese patients with excessive alcohol use. In addition to acetaldehyde, the shift in the
redox state during alcohol elimination may also inter link to other pathways and trigger downstream
effects leading to ALD. The knowledge gain from the studies of alcohol metabolism by these enzymes
may perhaps open the new avenue for the treatment of ALD [141].
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